Reassessment of the role of induction chemotherapy for head and neck cancer

被引:54
作者
Gibson, Michael K. [1 ]
Forastiere, Arlene A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Upper Aerodigest Program, Sidney Kimmel Comprehens Canc Ctr,Dept Oncol, Baltimore, MD 21231 USA
关键词
D O I
10.1016/S1470-2045(06)70757-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Head and neck cancers are a complex group of diseases defined by variations in histological features, anatomical location, and cause. Once the realm of surgeons and radiation oncologists, the treatment of locally advanced disease now involves medical oncologists. Major developments include primary chemoradiotherapy for unresectable disease and organ preservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radiation techniques, and biological therapies. Concomitant chemoradiotherapy consistently improves locoregional control. However, control of distant metastases is poor, resulting in an increasing proportion of deaths from systemic recurrence. Given this shift in site of recurrence, therapeutic strategies to suppress distant metastases may be the next goal for further improvement of survival. One approach that merits reassessment is the use of induction chemotherapy in the setting of locally advanced disease-both resectable and unresectable. In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials.
引用
收藏
页码:565 / 574
页数:10
相关论文
共 77 条
[31]   Evidence for a causal association between human papillomavirus and a subset of head and neck cancers [J].
Gillison, ML ;
Koch, WM ;
Capone, RB ;
Spafford, M ;
Westra, WH ;
Wu, L ;
Zahurak, ML ;
Daniel, RW ;
Viglione, M ;
Symer, DE ;
Shah, KV ;
Sidransky, D .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (09) :709-720
[32]  
Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO
[33]  
2-X
[34]   Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival [J].
Grandis, JR ;
Melhem, MF ;
Gooding, WE ;
Day, R ;
Holst, VA ;
Wagener, MM ;
Drenning, SD ;
Tweardy, DJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :824-832
[35]   Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience [J].
Haddad, R ;
Colevas, AD ;
Tishler, R ;
Busse, P ;
Goguen, L ;
Sullivan, C ;
Norris, CM ;
Lake-Willcutt, B ;
Case, MA ;
Costello, R ;
Posner, M .
CANCER, 2003, 97 (02) :412-418
[36]   Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: A phase II trial of the Minnie Pearl Cancer Research Network [J].
Hainsworth, JD ;
Meluch, AA ;
McClurkan, S ;
Gray, JR ;
Stroup, SL ;
Burris, HA ;
Yardley, DA ;
Bradof, JE ;
Yost, K ;
Ellis, JK ;
Greco, FA .
CANCER JOURNAL, 2002, 8 (04) :311-321
[37]  
Haraf DJ, 2003, CLIN CANCER RES, V9, P5936
[38]   Hypoxia - A key regulatory factor in tumour growth [J].
Harris, AL .
NATURE REVIEWS CANCER, 2002, 2 (01) :38-47
[39]   Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? [J].
Harrison, L ;
Blackwell, K .
ONCOLOGIST, 2004, 9 :31-40
[40]   Impact of tumor hypoxia and anemia on radiation therapy outcomes [J].
Harrison, LB ;
Chadha, M ;
Hill, RJ ;
Hu, K ;
Shasha, D .
ONCOLOGIST, 2002, 7 (06) :492-508